ULURU Inc. (NYSE Alternext: ULU) announced today that it has signed a worldwide distribution agreement appointing Novartis the exclusive distributor of a veterinary version of Altrazeal® for marketing to the animal health sector.
Under the terms of the agreement [ deal, contract ] ULURU will supply [ provide ] Novartis with finished product for marketing in the global [ international, worldwide ] markets. The agreement includes other wound care products that may be developed by ULURU that the parties mutually agree to be covered by this agreement.
Commenting on the agreement, Kerry P. Gray, President and CEO of ULURU, stated,
"We are very pleased to be working with Novartis, a leading global animal health care company and one of the top 5 pharmaceutical companies in the world. Initial wound healing testing in animals with Altrazeal® produced positive results."
"We look forward to working with the Novartis team to establish our wound franchise as a leader in the veterinary market."